CDSCO Panel Approves Johnson and Johnson's Protocol Amendment Proposal to study anti-cancer drug Amivantamab

Written By :  Dr. Divya Colin
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-07-14 12:00 GMT   |   Update On 2024-07-14 12:00 GMT
Advertisement

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved the drug major Johnson and Johnson's protocol amendment proposal to study the anti-cancer drug Amivantamab (JNJ-61186372) with the condition that an interim analysis report before the LTE (long-term extension) phase shall be submitted to CDSCO.

This came after the firm presented protocol amendment 3 dated 07 August 2023, protocol no. 61186372NSC3001. This is a randomized, open-label phase 3 study of combination Amivantamab and Carboplatin-Pemetrexed therapy, compared with carboplatin-pemetrexed, in patients with EGFR Exon 20ins-mutated locally advanced or metastatic non-small cell lung cancer.

Amivantamab is an EGF and MET receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation.

At the recent SEC meeting for oncology held on June 18, 2024, the expert panel reviewed protocol amendment 3 dated 07 August 2023 protocol no. 61186372NSC3001 presented by the drug major Johnson and Johnson.

After detailed deliberation, the committee recommended the approval of the protocol amendment as presented by the firm, with the condition that an interim analysis report before the LTE phase be submitted to CDSCO.

Also Read: Sun Pharma Industries Gets CDSCO Panel Nod to assess safety and efficacy of Relugolix Tablets for advanced prostate cancer

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News